397 related articles for article (PubMed ID: 12082624)
1. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
2. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
3. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
4. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
5. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
6. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
8. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
[TBL] [Abstract][Full Text] [Related]
9. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
11. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
12. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.
Morris MR; Hesson LB; Wagner KJ; Morgan NV; Astuti D; Lees RD; Cooper WN; Lee J; Gentle D; Macdonald F; Kishida T; Grundy R; Yao M; Latif F; Maher ER
Oncogene; 2003 Oct; 22(43):6794-801. PubMed ID: 14555992
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
14. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
[TBL] [Abstract][Full Text] [Related]
15. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
Lo KW; Kwong J; Hui AB; Chan SY; To KF; Chan AS; Chow LS; Teo PM; Johnson PJ; Huang DP
Cancer Res; 2001 May; 61(10):3877-81. PubMed ID: 11358799
[TBL] [Abstract][Full Text] [Related]
16. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.
Kuzmin I; Gillespie JW; Protopopov A; Geil L; Dreijerink K; Yang Y; Vocke CD; Duh FM; Zabarovsky E; Minna JD; Rhim JS; Emmert-Buck MR; Linehan WM; Lerman MI
Cancer Res; 2002 Jun; 62(12):3498-502. PubMed ID: 12067994
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.
Kuzmin I; Liu L; Dammann R; Geil L; Stanbridge EJ; Wilczynski SP; Lerman MI; Pfeifer GP
Cancer Res; 2003 Apr; 63(8):1888-93. PubMed ID: 12702579
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
[TBL] [Abstract][Full Text] [Related]
19. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract][Full Text] [Related]
20. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
